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Objectives. We sought to determine whether the results of the
first Coronary Angioplasty Versus Excisional Atherectomy Trial
(CAVEAT-I) influenced subsequent practice patterns among the
investigators.
Background. CAVEAT-I demonstrated that directional coro-
nary atherectomy (DCA) resulted in higher rates of early compli-
cations at a higher cost and with no clinical benefit. We sought to
determine whether these results influenced subsequent use of
procedures among CAVEAT-I investigators.
Methods. We compared the results of a week-long registry of all
coronary interventions performed at 35 CAVEAT-I sites in 1994
with those of a similar registry obtained in 1992 before the trial,
the results of which were published in 1993. For control purposes,
the use of procedures was studied at 24 additional sites to provide
insight into practice at hospitals not participating in the trial. A
total of 1,465 interventions were analyzed.
Results. Ninety-four percent of CAVEAT-I sites responded.
Utilization rates differed between CAVEAT-I and CAVEAT-I
follow-up (p < 0.001). Balloon angioplasty decreased from 83.8%
to 68.5%, DCA increased slightly from 10.7% to 14.1%, and the use
of other devices increased from 5.4% to 17.5%. Stand-alone
balloon use was more prevalent at nonparticipating control sites
than at sites that took part in CAVEAT-I (p < 0.001).
Conclusions. Paradoxically, despite the negative findings of
CAVEAT-I, there was a noteworthy trend toward an increase in
the use of DCA and other devices at CAVEAT-I sites. Our findings
suggest that among investigators in the trial, there may have been
a lack of influence of trial data on clinical practice patterns 1 year
after publication of the results. Ethics of protocol: Both CAVEAT
I and II were approved by the Institutional Review Board at each
study site.
(J Am Coll Cardiol 1998;31:265–72)
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Percutaneous transluminal coronary balloon angioplasty
(PTCA), first performed in 1977 by Gruentzig et al. (1), gained
acceptance and entered routine clinical practice without a
controlled clinical trial (2). Clinical experience and carefully
collated, multicenter observational data soon identified its
limitations, including a 3% to 5% incidence of abrupt closure
(resulting in myocardial infarction, emergency coronary artery
bypass graft surgery or death) and a 30% to 50% incidence of
restenosis (3).
Seeking to improve on the results of stand-alone balloon
angioplasty, aggressive investigation of newer devices began in
the mid-1980s (4). These devices included directional, rota-
tional and extractional atherectomy, laser angioplasty and
stents. Based on the attractive notion that plaque removal
rather than compression was the preferred strategy, Simpson
introduced directional atherectomy in 1984. Directional coro-
nary atherectomy (DCA) was approved in October 1990 by the
Food and Drug Administration (FDA) on the basis of data
from a multicenter observational registry of 838 consecutive
patients (2,5).
CAVEAT-I tested the hypothesis that DCA was superior to
PTCA for treating native primary coronary lesions amenable
to either intervention (6). This was the first large-scale, ran-
domized trial of a new device in cardiovascular medicine.
A total of 1,012 patients were randomized at 35 investiga-
tional sites in North America and Europe. Over 70% of all
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eligible patients and 30% of all atherectomy procedures per-
formed at the study sites were randomized into the study (see
Appendix for inclusion/exclusion criteria). The trial demon-
strated that DCA resulted in higher rates of early complica-
tions at a higher cost and with no clinical benefit. The study
results were initially presented at the American Heart Associ-
ation meeting in November 1992 (7), followed by full publica-
tion in the New England Journal of Medicine in July 1993 (6).
The purpose of the current study was to establish whether
the results of CAVEAT-I influenced subsequent practice
patterns among investigators in the trial. Because of the
negative results of atherectomy, we hypothesized that physi-
cians in the trial would use PTCA more often than DCA after
learning the results of the trial that they had participated in.
Methods
Surveys. In 1992, before CAVEAT-I, a 1-week long regis-
try of all coronary interventions performed at 35 CAVEAT-I
sites was collated by questionnaires sent by mail to site
coordinators. The questionnaire sought to establish angina
history, coronary anatomy and specific coronary procedures in
the baseline study group. After publication of the trial results
in July 1993, we compared the results of a slightly simplified
follow-up survey performed from April 18 to 22, 1994 (Fig. 1)
with those results obtained in 1992.
For control purposes, the use of procedures was studied at
24 additional sites to provide insight into practices at hospitals
not participating in the trial. These sites had randomized
patients in CAVEAT-II (8) (comparing DCA and PTCA in
vein grafts), and therefore had a readily available mechanism
for data collection.
Abbreviations and Acronyms
CAVEAT 5 Coronary Angioplasty Versus Excisional Atherectomy
Trial
DCA 5 directional coronary atherectomy
FDA 5 Food and Drug Administration
PTCA 5 percutaneous transluminal coronary angioplasty
Figure 1. Sample of survey question-
naire.
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Definitions. For the purposes of this study, three categories
of interventional therapy were identified. “Balloon” was de-
fined as stand-alone standard balloon, long balloon or perfu-
sion balloon angioplasty, or a combination. “Atherectomy” was
defined as any coronary intervention inclusive of stand-alone
DCA. “Other devices” was defined as any intervention (single
or combined) other than stand-alone balloon angioplasty or
atherectomy as previously defined (Table 1).
Statistics. Descriptive statistics were calculated for clinical
characteristics, procedural indications, coronary anatomy, spe-
cific intervention and investigational sites of the study group
during both surveys. Post-trial follow-up data from the
CAVEAT-I sites, CAVEAT-II (control) sites and the combi-
nation of both groups of sites were compared with one another
and with pretrial CAVEAT-I data using the chi-square test.
Ninety-five percent confidence intervals were calculated for
each type of intervention. Pretrial and post-trial interventions
were also compared by location of investigational site (United
States, Europe or Canada) using the chi-square test.
Six factors were assessed to identify independent predictors
of type of intervention. These factors were gender, reason for
revascularization, previous percutaneous intervention, vessel
type (native vs. vein graft), site of intervention (United States
vs. other country) and anatomy (left anterior descending vs.
other coronary artery). First, chi-square analysis was used to
identify univariate predictors of intervention type. Next, fac-
tors that were univariately significant at p , 0.15 were consid-
ered in a stepwise logistic regression model. A factor entered
the model at p , 0.15 and remained in the model at p , 0.05.
Two models were evaluated: one with DCA as the outcome
versus the other two interventions (balloon angioplasty/other
devices), and the other with balloon angioplasty as the out-
come versus the other two interventions (DCA/other devices).
Results
Survey response. Baseline pretrial 1992 CAVEAT-I uni-
verse survey data were obtained from 643 patients at 34
CAVEAT-I sites. The site response rate was 97% (34 of 35
sites). Composite data for the present study were obtained
from 1,040 patients undergoing 1,465 interventions at 57
CAVEAT sites. Of these patients, 647 underwent an interven-
tion at sites that had partaken in CAVEAT-I, whereas 393 did
so at “control” sites that had not participated. The post-trial
survey response rate was 94.3% of sites (33 of 35) that took
part in CAVEAT-I, but 97% (33 of 34) of those CAVEAT-I
sites that participated in the baseline survey. The only
CAVEAT-I site that did not collate pretrial survey data at
baseline did not participate in this follow-up. Among
CAVEAT-II post-trial “control” sites, the response rate was
100% among the 19 new centers that randomized patients
in CAVEAT-II. Along with those sites that had taken part in
CAVEAT-I, a total of 54 sites randomized patients in
CAVEAT-II. While the original CAVEAT-I pretrial baseline
data base consisted only of sites in the United States and
Europe, a number of Canadian sites enrolled patients in
CAVEAT-II.
Descriptive statistics. Patients who underwent interven-
tions during the study period ranged in age from 19 to 93 years
(mean 63 6 11.4). Two-thirds were men (69.1%), and the most
common indication for intervention was unstable angina
(74%). Only 3.5% of interventions were part of an ongoing
randomized study, indicating that the choice of interventional
strategy was almost universally driven by physician preference.
Thirty-six percent (36.2%) of patients had a previous myocar-
dial infarction, whereas 33.6% had undergone a previous
percutaneous intervention. Most interventions (86.5%) were
performed on native coronary lesions, and most patients had
single- (45.8%) or double-vessel (32.4%) disease. Based on
characteristics for which comparative data are available, the
target group was broadly similar to the baseline group. One or
two interventional devices were used in 93.1% of patients
(mean 1.4 6 0.7 devices).
All major comparisons of post-trial CAVEAT-I, CAVEAT-
II (control sites) and the combined post-trial survey data set
with the CAVEAT-I pretrial baseline universe were statisti-
cally significant (p , 0.001) (Table 2). At CAVEAT-I sites, the
percentage of patients undergoing stand-alone balloon angio-
plasty decreased significantly (83.8% to 68.5%) since CAVE-
AT-I; the percentage treated with DCA remained stable
(10.7% to 14.1%); and the percentage of those undergoing
other device interventions increased significantly (5.4% to
17.5%). A comparison of post-trial CAVEAT-II (control) data
with pretrial CAVEAT-I data also revealed differences in use
of stand-alone balloon angioplasty, DCA and other devices in
1994 compared with patterns in 1993 (p , 0.001). Interestingly,
post-trial stand-alone balloon use was more prevalent at
CAVEAT-II (community control) sites than at sites that
originally took part in CAVEAT-I (78.1% vs. 68.5%, p ,
0.001), suggesting a gradient of device use from sites that had
participated in CAVEAT-I to control sites that had not.
Analysis. Analysis of interventions by study site location
(United States, Europe and Canada) revealed that interval
changes in utilization of devices was most evident among U.S.
Table 1. Definition and Classification of Interventions
Intervention Classification
Frequency (no. of pts)
CAVEAT-I
CAVEAT-II
(control)Baseline Follow-Up
Balloon only Balloon 539 443 307
DCA only DCA 42 57 23
Other intervention
only
Other 35 62 22
DCA and other DCA — 3 —
Balloon and other Other — 51 25
Balloon and DCA DCA 27 28 14
Balloon, DCA and
other
DCA — 3 2
Total 643 647 393
CAVEAT 5 Coronary Angioplasty Versus Excisional Atherectomy Trial;
DCA 5 directional coronary atherectomy; pts 5 patients.
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investigators (p , 0.0001) (Tables 3 and 4). Interval differences
in utilization in the small sample of international sites were of
marginal statistical significance (p 5 0.047). These estimates
may, however, be unstable. Directional atherectomy, for exam-
ple, went from a 0.0% to 12.0% rate of use among the
European sites after CAVEAT-I. In comparison with Europe
and Canada, there does seem to be relatively greater overall
use of devices at U.S. CAVEAT sites. However, the sparse
number of CAVEAT sites in Europe and Canada dictates
caution in generalizing this observation.
In the regression model, factors found to be independently
predictive of use of DCA were gender (more often in men than
in women), U.S.-based investigational site and lesion location
in the left anterior descending coronary artery (Table 5).
Vessel type (more often in native than in vein grafts) may also
have been predictive. Although a trend in favor of use in the
proximal segment of the left anterior descending coronary
artery was evident, DCA was frequently used in other ana-
tomic segments and vessel sites. Approximately 40% of overall
DCA use was either in the right or left circumflex vessels.
Discussion
In the current study, we sought to establish whether the
findings of CAVEAT-I, published in a major peer-reviewed
journal (6), modulated the practice of DCA among physician-
investigators who designed the trial, participated in it and
subsequently co-authored publication of its results.
Summary of findings. CAVEAT-I found that patients ran-
domized to DCA had higher angiographic gain. However,
there were more acute complications and greater costs were
incurred, with no apparent clinical benefit at 6 months (6).
Furthermore, at 12 months there was a persistent excess of
cumulative deaths and the composite of death and nonfatal
myocardial infarction in the group randomized to DCA (9).
In follow-up, we found that there had been a significant
decline in the proportion of procedures relying exclusively on
balloon angioplasty and paradoxically, despite the negative
results of CAVEAT-I, a noteworthy trend toward an increase
in the use of DCA and other devices at CAVEAT sites. These
results suggest that among investigators in the trial, there may
have been a lack of influence of CAVEAT-I data on clinical
Table 2. Frequency of Interventions at Follow-Up Compared With Original CAVEAT-I Data
Intervention
CAVEAT-I
CAVEAT-II
(control: n 5 393)
Combined Data*
(n 5 1,040)
Baseline
(n 5 643)
Follow-Up
(n 5 647)
Balloon
No. (%) of pts 539 (83.8%) 443 (68.5%) 307 (78.1%) 750 (72.1%)
95% CI 80.9–86.7 64.9–72.1 74.0–82.2 69.4–74.8
DCA
No. (%) of pts 69 (10.7%) 91 (14.1%) 39 (9.9%) 130 (12.5%)
95% CI 8.3–13.1 11.4–16.8 6.9–12.9 10.5–14.5
Other
No. (%) of pts 35 (5.4%) 113 (17.5%) 47 (12.0%) 160 (15.4%)
95% CI 3.6–7.2 14.6–20.4 8.8–15.2 13.2–17.6
Vs. CAVEAT-I p , 0.001 p , 0.001 p , 0.001
*CAVEAT-I follow-up group plus CAVEAT-II control group. CI 5 confidence interval; other abbreviations as in
Table 1.
Table 3. Comparison of Frequency of Interventions by Study Site Location
Intervention
CAVEAT-I
CAVEAT-II (control)
[no. (%) of pts]
Baseline
[no. (%) of pts]
Follow-Up
[no. (%) of pts]
U.S. Europe U.S. Europe U.S. Europe Canada
Balloon 508 31 406 37 212 18 77
(83.3%) (93.9%) (68.0%) (74.0%) (73.1%) (81.8%) (95.1%)
DCA 69 0 85 6 36 2 1
(11.3%) (0.0%) (14.2%) (12.0%) (12.4%) (9.1%) (1.2%)
Other 33 2 106 7 42 2 3
(5.4%) (6.1%) (17.8%) (14.0%) (14.5%) (9.1%) (3.7%)
Total 610 33 597 50 290 81 22
U.S. 5 United States; other abbreviations as in Table 1.
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practice patterns in 1994—a full year after publication of the
results.
Why did CAVEAT have no apparent effect on investigator
practice? Acceptance of trial results is probably influenced by
pretrial probability, based on perceptions of treatment efficacy.
If pretrial views about a device are extremely positive or
negative, results in a direction opposite to the baseline assump-
tion are less likely to make an impact. Additional trials may
then be needed to produce a real change in physician practice
and to resolve the tension between policy and culture. Like-
wise, if pretrial views were of intermediate certainty, a well
formulated trial might be expected to provide “definitive”
assurance. Curiously, the results of the Canadian atherectomy
trial were published in the same issue of the New England
Journal of Medicine (10). The simultaneous appearance of two
negative trials might have been expected to edify the conclu-
sions of each one.
CAVEAT-I was performed in the early years of the new
device era, characterized by a momentum of novelty and
preoccupation with lumen debulking (11). The new device
allure may have contributed to a general expectation that
atherectomy would prevail. Because the directionality of the
results was at odds with data from premarket approval obser-
vational registries (2), the degree to which DCA in CAVEAT-I
simulated application in the “real-world” became a theme for
counter-marketing.
Like other debulking technologies, DCA has the potential
to achieve better angiographic outcomes with significant im-
mediate gratification to the operator. Looking back, many
investigators thought the performance of DCA in CAVEAT
was not aggressive enough. Curiously, however, most did
believe at the time of the study that they had performed
“aggressive” atherectomy. Discrepancies only became appar-
ent when subjective site assessments were compared with
objective core-laboratory measurements using worst projection
analysis. The level of safety at which a “bigger” lumen obtained
by cutting becomes “better” for the patient remains an unan-
swered question. However, there is a dissociation between
clinical and angiographic end points, a phenomenon that has
only recently begun to be appreciated (12).
A commonly cited issue in explaining the lack of impact of
clinical trials relates to the similarity between the “study” and
“practice” groups. To address this issue, we performed an
exploratory analysis comparing clinical and gross anatomic
characteristics of patients in the trial with those of patients at
all sites surveyed for the purpose of this analysis (Table 6).
Among variables common to both data sets, we found minor
but statistically significant differences in the proportion of
patients undergoing an intervention who had a history of
myocardial infarction or unstable angina. Although these
observations are interesting, it is important to keep in mind
that statistical significance does not necessarily translate into
clinical significance. The randomized study group also included
a greater frequency of patients with single-vessel disease—an
observation that has also been made in the major thrombolytic
trials. More extensive disease in the 1994 practice group might
have been expected to result in even greater caution in the use
of DCA.
However, the desire of competing physicians, medical cen-
ters and the medical industry to offer the “newest, brightest
and most sophisticated” technologies in practice (13) may have
sustained a positive feedback loop of referrals. The observed
gradient of post-trial device use between CAVEAT-I follow-up
and CAVEAT-II (control) sites might have been due to this
phenomenon.
The issue of when clinical trials should be conducted during
Table 5. Stepwise Logistic Regression Analysis*
Intervention and Independent
Factors p Value OR (95% CI)
DCA (n 5 959) (model includes
vessel type)
Gender (M/F) 0.029 1.65 (1.05–2.58)
Vessel type (native/SVG) 0.054 2.02 (0.99–4.13)
Study site (U.S./C or E) 0.007 4.15 (1.49–11.63)
LAD (Y/N) , 0.001 2.39 (1.62–3.54)
DCA (n 5 959) (model excludes
vessel type)
Gender (M/F) 0.034 1.62 (1.04–2.54)
Study site (U.S./C or E) 0.008 3.98 (1.43–11.11)
LAD (Y/N) , 0.001 2.50 (1.69–3.69)
Balloon (n 5 980)
Vessel type (native/SVG) 0.004 1.77 (1.19–2.62)
Study site (U.S./C or E) , 0.001 3.83 (1.96–7.50)
LAD (Y/N) 0.005 1.52 (1.14–2.02)
*Analysis includes patients with complete data only. C or E 5 Canada or
Europe; F 5 female; LAD 5 left anterior descending coronary artery; M 5
male; N 5 no; OR 5 odds ratio; SVG 5 saphenous vein graft; Y 5 yes; other
abbreviations as in Tables 1 to 3.
Table 4. Statistical Comparisons of Frequency of Interventions by
Study Site Location
Site p Value
American
Ia, Fa, IIa , 0.0001
Ia vs. Fa , 0.0001
Ia vs. IIa , 0.0001
Fa vs. IIa 0.29
European
Ie, Fe, IIe 0.20
Ie vs. Fe 0.047
Ie vs. IIe 0.18
Fe vs. IIe 0.77
CAVEAT-I
Ia vs. Ie 0.11
CAVEAT-I follow-up
Fa vs. Fe 0.68
CAVEAT-II control
IIa, IIe, IIc 0.0011
IIa vs. IIe 0.66
IIa vs. IIc , 0.0001
IIe vs. IIc 0.08
I 5 CAVEAT-I; II 5 CAVEAT-II; a 5 United States; c 5 Canada; e 5
Europe; F 5 follow-up; other abbreviations as in Table 1.
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the life cycle of a new device is a generic one common to all
device investigations (2). After the CAVEAT-I trial was
initiated, newer product lines with improved handling charac-
teristics, such as newer generation SCA-EX devices and the
Atherocath-GTO, were released. Whether these devices, if
available earlier, would have affected the results of CAVEAT
is unknown.
In a post hoc CAVEAT-I subgroup analysis, clinical site
remained a statistically significant predictor of acute gain after
adjustment for device size, lesion location, vessel diameter and
diabetes (14). Bearing in mind the statistical limitation of such
analyses, this raises the possibility that the composite multi-
center result did not reflect uniformly optimal device use.
Indeed, many investigators pointed to other investigators and
sites as being responsible for the negative results of the trial! In
the Balloon Versus Optimal Atherectomy Trial (BOAT) (15),
which began on May 9, 1994, only one “certified” investigator
per site was allowed. It is not clear that this is the solution to
the dilemma.
In part owing to the embryonic state of the field, there was
early controversy over the thresholds for significant creatine
kinase release in the setting of interventional procedures and
“composite” outcome measures, which combined death, myo-
cardial infarction and target vessel revascularization. Some
physicians thought postintervention myocardial infarctions
were meaningless. Some of these issues have since become
better understood (16).
The paradoxic increase in DCA and other device use was
particularly evident in U.S. sites. Other recent international
studies have also found international differences in technology
intensity (17). Furthermore, corporate sales data revealed a
devices for vascular intervention worldwide sales plateau in
1994 at $80 million, although domestic (United States) sales
increased by 10% to 11% (18). Directional atherectomy com-
prised 14% of interventions in the United States but only ,3%
in Europe. It is conceivable that investment of professional
careers in new coronary devices by U.S.-based investigators
played a role in making acceptance of CAVEAT-I results
difficult.
Other factors may also have played a role. Directional
atherectomy specimens were required for bench research
purposes in at least one site. Directional atherectomy has
continued to be reimbursed without limitations or conditions
by third-party payors, and access to resources has been rela-
tively unlimited at the study sites participating in this survey.
The FDA made no changes in approved indications for the
technique despite the findings of CAVEAT-I. However, the
FDA approved, or was in the process of approving, other new
devices during the same time frame as the CAVEAT studies.
These parallel events may have fueled the momentum for new
device use in multiple permutations and combinations.
In summary, the following factors may have played a role in
the lack of influence of CAVEAT’s data: positive pretrial views
on atherectomy; the allure of a new device that had the
potential to achieve better angiographic results; the desire of
competing physicians and hospitals to have and use the newest
technology; and the possibility that the composite results did
not reflect uniformly optimal device use.
Comparison with other clinical trials. To our knowledge,
our study is the first to specifically investigate the impact of a
trial on the practice of investigators. Previous published data
suggest that clinical trials can lead to changes in practice in the
community, although usually after a period of lag (19,20).
More recently, Lamas et al. (21) concluded that well executed
clinically relevant trials published in highly visible journals had
an early measurable impact on clinical use of aspirin and
calcium antagonists. The Gruppo Italiano per lo Studio della
Streptochinasi nell’Infarto Miocardico (GISSI) trials suggested
that a culture of integration of clinical trial methodology into
routine practice helped subsequent acceptance of results (22).
In a separate study, the level of use of thrombolytic agents in
a region of England mirrored previous participation in multi-
center trials of thrombolysis (23,24). In none of these situa-
tions, however, were operator-investigators themselves on
trial—a factor presumably peculiar to new device investigation.
How the researchers and sponsors of trials interact with one
another and with the rest of the health care community is a key
factor in determining impact (25). In the United States, the
National Registry of Myocardial Infarction exemplifies a
mechanism for educating physicians and hospitals on the
Table 6. Comparison of Clinical and Anatomic Characteristics of
CAVEAT-I Group With Post-Trial Survey Registry Group
Variable
CAVEAT-I Group
[no. (%) of pts]
Entire Follow-Up
Survey Group*
[no. (%) of pts] p Value
Gender
Male 734 (72.5%) 690 (69.1%) 0.09
Female 278 (27.5%) 309 (30.9%)
History of MI
Yes 430 (42.5%) 346 (36.2%) 0.004
No 582 (57.5%) 610 (63.8%)
Unstable angina
Yes 688 (68.0%) 710 (74.0%) 0.003
No 324 (32.0%) 249 (26.0%)
No. of diseased vessels
1 663 (65.5%) 431 (45.8%) , 0.001
2 293 (29.0%) 305 (32.4%)
3 56 (5.5%) 206 (21.9%)
If unstable angina
Pain at rest
Yes 309 (44.9%) 175 (25.5%) , 0.001
No 379 (55.1%) 511 (74.5%)
Pain with ECG changes
Yes 134 (19.5%) 127 (18.5%) 0.65
No 554 (80.5%) 559 (81.5%)
Angina after MI
Yes 117 (17.0%) 80 (11.7%) 0.005
No 571 (83.0%) 606 (88.3%)
Accelerating pattern
Yes 426 (61.9%) 342 (49.9%) , 0.001
No 262 (38.1%) 344 (50.2%)
*Only complete data used. ECG 5 electrocardiographic; MI 5 myocardial
infarction; other abbreviations as in Table 1.
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clinical use of thrombolytic therapy after the major thrombo-
lytic trials.
Study limitations. Our follow-up survey was designed to
last 1 week, primarily because the baseline survey was obtained
over a 1-week period. It is conceivable that either sample was
unrepresentative of the range of practice over a longer period
of time. There were too few study sites in Canada and Europe
to make generalizations about practice in those countries.
However, 1994 worldwide interventional cardiology financial
data reveal market proportions of next-generation devices and
balloon angioplasty that are consistent with our observations in
the CAVEAT follow-up data base (18).
For reasons of cost and compliance, we did not document
detailed comparative information on lesion morphology and
vessel size. It is conceivable that evolution of referral patterns
over time might have led to a peculiar aggregation of new
device–requiring lesions at CAVEAT sites.
Last, and perhaps most important, an alternative explana-
tion of our results could be that the trial blunted what might
otherwise have been a steep rise in the use of atherectomy had
the results been more positive. Indeed, the observation that
14% of U.S. sites in 1994 used DCA was at odds with expected
corporate sales projected at 25% (18).
Study implications. Our study supports the need to better
understand the dynamics of acceptance of study data after
randomized, controlled trials of medical devices, particularly
among operator-investigators (26,27). A lack of enthusiastic
dissemination of trial results and implications to noninvestiga-
tor practitioners and policymakers by researchers and study
sponsors could limit rapid translation of study results to
practice (28). Merely publishing the results of a well designed
study in an influential journal is not enough to effect a rapid
change in practice pattern, as was suggested in a previous
report (21).
Incorporation of randomized, controlled data into practice
guidelines, quality improvement programs and medical neces-
sity assessments by third-party payors might help facilitate
evidence-based practice in an era when informed judgments
must be made in the setting of declining resources. However,
implementation of trial results needs to be balanced against
the tide of rapidly evolving technology and the uncertainties
that go along with it. Clinical trial design may need to be
critically reevaluated to address this problem (29).
Research and development of a combined AtheroCath-
Ultrasound catheter, may lead to safer, lesion-specific and
more truly directional atherectomy procedures. Lesion-specific
trials may emerge as a clinical trial strategy in the future (30).
With the passage of time since CAVEAT, however, it would
appear that the focus has shifted away from balloon angio-
plasty as a point of reference. Directional atherectomy must
now demonstrate superiority over stents (31,32).
Conclusions. After CAVEAT-I, there was a significant
decline in the proportion of interventions relying exclusively on
balloon angioplasty, and paradoxically, despite its negative
findings, a noteworthy trend toward an increase in the use of
DCA and other devices at CAVEAT-I sites. Our findings
suggest that among investigators in the trial, there may have
been a lack of influence of CAVEAT-I data on clinical practice
patterns in 1994, 1 year after full publication and 2 years after
the results were known. However, we acknowledge that the
pattern of DCA use in our survey may have been transient, as
there has subsequently been a decline in 1995 to 1996 due to
the emergence of stents as an approved interventional device.
Appendix
Inclusion and Exclusion Criteria: CAVEAT I and II
CAVEAT I
Inclusion Criteria
1. Patients who had ischemic heart disease deemed suitable for either
atherectomy or angioplasty who were willing to give written in-
formed consent.
2. Presence of diseased native coronary vessels that had not under-
gone a previous coronary intervention, that had stenosis of at least
60% on visual assessment and a lesion length of #12 mm and that
were suitable for either a $6F cutter or a $3.0-mm balloon.
3. Patients with multivessel coronary disease were eligible, but a single
vessel was specified as the target before coronary intervention began.
4. All lesions had to be amenable to both techniques.
CAVEAT II
Inclusion Criteria
1. Patients with primary vein graft lesions suitable for .6F atherec-
tomy catheter (.3.0 mm); a subtotal diameter stenosis .60% and
,100% by visual assessment; and lesion length ,12 mm.
2. If more than one lesion was present in the vein graft, all had to be
amenable to either technique.
Exclusion Criteria
1. Patients who had a myocardial infarction in the previous 5 days.
2. Participation in another study.
3. Restenotic lesion.
4. Investigator preference not to randomize.
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